Skip to main content

Table 1 Clinical and laboratory data at baseline and 3 and 6 months of follow-up

From: Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus

Variables

Baseline

Follow up (90 days)

Follow up (180 days)

p value

 

80.78 ± 15.91

79.98 ± 14.98

80.52 ± 15.63

0.12

BMI (kg/m2)

31.18 ± 5.42

30.85 ± 5.09

31.03 ± 5.17

0.82

WHR (cm)

101.77 ± 11.24

100.67 ± 10.21

100.53 ± 10.71

0.12

HbA1c (%)

7.61 ± 1.53

7.58 ± 1.44

7.68 ± 1.50

0.713

Cholesterol (mg/dl)

189.33 ± 40.78

191.17 ± 38.39

190.03 ± 42.12

0.945

Triglycerides (mg/dl)

142.53 ± 75.12

186.17 ± 162.79

185.28 ± 139.27

0.088

LDL Chol (mg/dl)

114.59 ± 32.93

109.50 ± 31.18

109.19 ± 33.78

0.463

HDL Chol (mg/dl)

48.51 ± 10.39

48.83 ± 9.07

46.89 ± 10.24

0.242

Vitamin B12 (pg/dl)

293.91 ± 126.54

287.46 ± 122.65

291.57 ± 132.26

0.844

CRP (mg/dl)

0.352 ± 0.31

0.431 ± 0.28

0.372 ± 0.35

0.327

AER (mg/min)

21.04 ± 53.24

27.44 ± 77.76

27.36 ± 75.76

0.309

  1. Data are presented as means ± standard deviation.
  2. Abbreviations: BMI: Body mass index; WHR: Waist/hip ratio;
  3. HbA1C: glycated haemoglobin; CRP: C-reactive protein; AER: Albumin Excretion rate